Scarica l'app Stockscreener
121.05
1.04%
1.25
Dopo l'orario di chiusura:
121.04
-0.010
-0.01%
Precedente Chiudi:
$119.80
Aprire:
$119.98
Volume 24 ore:
466.85K
Relative Volume:
0.56
Capitalizzazione di mercato:
$10.07B
Reddito:
$51.48M
Utile/perdita netta:
$-315.00M
Rapporto P/E:
-33.90
EPS:
-3.5708
Flusso di cassa netto:
$-244.00M
1 W Prestazione:
-0.30%
1M Prestazione:
+9.48%
6M Prestazione:
+33.01%
1 anno Prestazione:
+174.49%
Intervallo 1D:
$116.46
$121.56
Intervallo di 1 settimana:
$116.46
$127.36
Portata 52W:
$39.84
$130.05
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Nome
Kymera Therapeutics Inc
Settore
Industria
Telefono
857-285-5314
Indirizzo
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
121.05 | 10.10B | 51.48M | -315.00M | -244.00M | -3.5708 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-05-06 | Iniziato | Canaccord Genuity | Buy |
| 2026-03-16 | Ripresa | Jefferies | Buy |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2026-01-06 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-11-03 | Ripresa | Guggenheim | Buy |
| 2025-10-24 | Reiterato | B. Riley Securities | Buy |
| 2025-10-21 | Iniziato | Mizuho | Outperform |
| 2025-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-16 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-07-30 | Ripresa | B. Riley Securities | Buy |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-06-03 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-05-20 | Ripresa | Stifel | Buy |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Market Perform |
| 2024-12-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2024-08-26 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | Iniziato | Oppenheimer | Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-01-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | Iniziato | Truist | Buy |
| 2023-05-05 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | Iniziato | Raymond James | Mkt Perform |
| 2022-08-15 | Iniziato | Jefferies | Buy |
| 2022-08-03 | Iniziato | Goldman | Buy |
| 2022-07-20 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-03-10 | Iniziato | JP Morgan | Neutral |
| 2022-02-10 | Iniziato | Wells Fargo | Overweight |
| 2021-09-30 | Iniziato | B. Riley Securities | Neutral |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-10 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-14 | Iniziato | Berenberg | Buy |
| 2020-12-04 | Iniziato | H.C. Wainwright | Buy |
| 2020-09-15 | Iniziato | BofA Securities | Neutral |
| 2020-09-15 | Iniziato | Cowen | Outperform |
| 2020-09-15 | Iniziato | Guggenheim | Buy |
| 2020-09-15 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Kymera Therapeutics Inc Borsa (KYMR) Ultime notizie
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Piper Sandler Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $140 - Moomoo
B of A, Truist raise Kymera Therapeutics price targets - scanx.trade
Eagle Health Investments LP Buys Shares of 166,148 Kymera Therapeutics, Inc. $KYMR - MarketBeat
Merck & Co. Inc. Takes Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
TimesSquare Capital Management LLC Purchases Shares of 157,327 Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics, Inc. $KYMR Shares Sold by Bank of America Corp DE - MarketBeat
Kymera Therapeutics (KYMR) Advances 3.42% to $121.41 as Protein Degradation Platform Gains Investor AttentionAnalyst Upgrade Stocks - vinanet.vn
Kymera Therapeutics Inc (KYMR) (Q2 2026) Earnings Call Highlight - GuruFocus
Kymera Therapeutics Stock Rockets 17% With 9-Day Winning Streak - Trefis
A 9-Day Winning Streak Has Kymera Therapeutics Stock Up 17% - Trefis
State of Wyoming Purchases New Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics (KYMR) Edges Higher by 1.4% as Shares Test Key Resistance at $121.87IV Spike - Vinanet
T. Rowe Price Associates (KYMR) reports 8.6% stake in Kymera Therapeutics - Stock Titan
Kymera Therapeutics Stock 8-Day Winning Spree: Stock Climbs 14% - Trefis
A 8-Day Winning Streak Has Kymera Therapeutics Stock Up 14% - Trefis
Atlas Venture funds (KYMR) report 3.4% beneficial stake in Kymera Therapeutics - Stock Titan
Stifel Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $132 - Moomoo
Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript - The Globe and Mail
Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR) - The Globe and Mail
Kymera Therapeutics (NASDAQ:KYMR) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
(KYMR) Volatility Zones as Tactical Triggers - Stock Traders Daily
HC Wainwright Issues Negative Outlook for KYMR Earnings - MarketBeat
BofA Securities Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Cuts Target Price to $123 - Moomoo
California State Teachers Retirement System Increases Stake in Kymera Therapeutics, Inc. $KYMR - MarketBeat
J.P. Morgan Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $121 - Moomoo
Why Kymera Therapeutics (NASDAQ:KYMR) Is Drawing Fresh Attention This Week? - Kalkine Media
A Quick Look at Today's Ratings for Kymera Therapeutics(KYMR.US), With a Forecast Between $116 to $139 - Moomoo
Q3 EPS Forecast for Kymera Therapeutics Cut by Analyst - MarketBeat
RBC Capital Downgrades Kymera Therapeutics(KYMR.US) to Hold Rating, Raises Target Price to $112 - moomoo.com
KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments - finance.yahoo.com
KYMR Maintains Overweight by Barclays -- Price Target Raised to $139 - GuruFocus
KYMERA THERAPEUTICS, INC. : CITIGROUP RAISES TARGET PRICE TO $135 FROM $120 - Bitget
Kymera Therapeutics (KYMR) Stock Faces A Revenue Durability Reckoning - simplywall.st
Accelerated KT-621 Trial and Narrower Loss Might Change The Case For Investing In Kymera Therapeutics (KYMR) - finance.yahoo.com
KYMR SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
KYMR Looks 328.3% Overvalued on GF Value™ - GuruFocus
Kymera Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Kymera Therapeutics, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:KYMR) 2026-08-05 - Seeking Alpha
Kymera Therapeutics, Inc. Stock 12‑Month Price Target Raised to $128.91, Implies 23% Upside - TradingView
Kymera Therapeutics (NASDAQ:KYMR) Releases Earnings Results, Beats Estimates By $0.09 EPS - MarketBeat
Kymera Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Kymera Therapeutics Q2 Earnings Call Highlights - MarketBeat
Is Kymera Therapeutics Inc (KYMR) Overvalued After Q2 Earnings B - GuruFocus
Earnings call transcript: Kymera beats Q2 2026 estimates on revenue surge - Investing.com
Kymera Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Kymera Therapeutics Q2 Net Loss Narrows, Collaboration Revenue Rises - marketscreener.com
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings Flash (KYMR) Kymera Therapeutics Posts Q2 Loss $0.62 a Share, vs. FactSet Est of $0.71 Loss - marketscreener.com
Earnings Flash (KYMR) Kymera Therapeutics, Inc. Reports Q2 Collaboration Revenue $65.0M, vs. FactSet Est of $32.8M - marketscreener.com
Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update - The Manila Times
Kymera Therapeutics Inc Azioni (KYMR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.00%
3.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):